ASH 2023 Leukemia/MDS/Myelofibrosis Highlights – TRANSFORM-1, MANIFEST-2, SAVE, AUGMENT-101 with Dr. Uma Borate

August 24, 2024
Conferences ASH 2023
Share This:

Key Points

TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis
SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML
AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results
Dr. Uma Borate
Profile

Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center

The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective.

Tags:
Dr. Uma Borate MDS/Myelofibrosis ASH 2023 Leukemia

Related Posts